Who are LY3537031's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Continue GLP/GIP, Treatment with tirzapatide, AC2993, IcoSema, DA5221-T2, DA5221-B2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ly3537031.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

LY3537031 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LY3537031 (LY3537031) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1/GIP receptor dual agonist. Area: Diabetes, Obesity.

phase 3 GLP-1/GIP receptor dual agonist GLP-1R, GIPR Diabetes, Obesity Small molecule Live · refreshed every 30 min

Target snapshot

LY3537031 (LY3537031) — Eli Lilly and Company. LY3537031 is a GLP-1 and GIP receptor dual agonist that activates both incretin pathways to improve glucose control and promote weight loss.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LY3537031 TARGET	LY3537031	Eli Lilly and Company	phase 3	GLP-1/GIP receptor dual agonist	GLP-1R, GIPR
Continue GLP/GIP	Continue GLP/GIP	The Cleveland Clinic	marketed	GLP-1/GIP receptor agonist	GLP-1R, GIPR
Treatment with tirzapatide	Treatment with tirzapatide	University Medical Centre Ljubljana	marketed	GLP-1/GIP receptor agonist	GLP-1R, GIPR
AC2993	AC2993	AstraZeneca	phase 3	Dual GLP-1/GIP receptor agonist	GLP-1R, GIPR
IcoSema	IcoSema	Novo Nordisk A/S	phase 3	GLP-1/GIP receptor agonist	GLP-1R, GIPR
DA5221-T2	DA5221-T2	Dong-A ST Co., Ltd.	phase 3	GLP-1/GIP receptor agonist	GLP-1R, GIPR
DA5221-B2	DA5221-B2	Dong-A ST Co., Ltd.	phase 3	GLP-1/GIP receptor agonist	GLP-1R, GIPR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1/GIP receptor dual agonist class)

Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LY3537031 — Competitive Intelligence Brief. https://druglandscape.com/ci/ly3537031. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing